EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐term outcomes of two‐dose alemtuzumab induction in pediatric kidney transplantation

Rachel M Engen iD, Sharon M Bartosh iD

Pediatric Transplantation · 2024

DOI: 10.1111/petr.14753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Rachel M Engen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Wisconsin Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Lymphopenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alemtuzumab is a lymphocyte depleting agent used for induction in kidney transplant, but long‐term information on its use in pediatric recipients remains sparse.

Methods

We performed a single‐center retrospective cohort study of 57 pediatric kidney transplant recipients receiving alemtuzumab 20 mg/m 2 /dose ×2 doses for induction immunosuppression. All patients underwent surveillance biopsies, and 91.3% underwent steroid withdrawal by day 4 post‐transplant. Outcomes of interest included graft survival, development of donor specific antibodies (DSA), incidence of viremia and PTLD, and duration of lymphopenia.

Results

Median follow‐up time was 7.9 years (IQR 5–13.6 years). Median graft survival was 16.5 years (95% CI 11.6‐unknown). DSA developed in 36.5% at a median of 944 days (IQR 252–2113 days). Incidences of BK polyomavirus DNAemia (BKPyV‐DNAemia), CMV DNAemia, and EBV DNAemia were 38.6%, 22.8%, and 14%, respectively; one patient developed PTLD at 13.3 years post‐transplant. Median duration of lymphopenia was 365 days (IQR 168–713 days); 19.3% of patients remained lymphopenic at 3 years post‐transplant. There was no association between duration of lymphopenia and graft survival, rejection, DSA detection, or viremia.

Conclusions

A two‐dose alemtuzumab induction protocol can have excellent outcomes with a steroid‐free maintenance immunosuppression regimen. More comprehensive, multicenter, comparative studies of pediatric kidney transplant are needed to improve long‐term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationLymphopeniaChildHumansAlemtuzumabGraft RejectionGraft SurvivalImmunosuppressive AgentsRetrospective StudiesSteroidsViremia

Stichwörter der Autor:innen

inductionlong‐term outcomespediatric kidney transplant

Substanzen

AlemtuzumabImmunosuppressive AgentsSteroids

Autor:innen und Institutionen

  • Department of Pediatrics, University of Wisconsin Madison, Madison, Wisconsin, USA.

ORCID-Profile: Rachel M Engen, Sharon M Bartosh

Zitieren

APA

Engen, R. M., & Bartosh, S. M. (2024). Long‐term outcomes of two‐dose alemtuzumab induction in pediatric kidney transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.14753

Vancouver

Engen RM, Bartosh SM. Long‐term outcomes of two‐dose alemtuzumab induction in pediatric kidney transplantation. Pediatric Transplantation. 2024. doi:10.1111/petr.14753

BibTeX
@article{Engen2024,
  author = {Engen, Rachel M and Bartosh, Sharon M},
  title = {Long‐term outcomes of two‐dose alemtuzumab induction in pediatric kidney transplantation},
  journal = {Pediatric Transplantation},
  year = {2024},
  doi = {10.1111/petr.14753}
}
Kostenlos starten →